We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
PharmAbcine Inc. (KOSDAQ: 208340ks) entered into a research collaboration with Wuxi Shuangliang Biotechnology (SLBio) to evaluate the combination of each party's clinical candidate, olinvacimab and C-005, a 3rd generation of EGFR inhibitor with superior b
To evaluate olinvacimab and C-005, a 3rd generation of EGFR inhibitor with superior brain-blood-barrier permeability in treating non-small cell lung cancer.